Leflunomide in Combination With Vemurafenib in Patients With V600 Mutant Metastatic Melanoma

Trial Profile

Leflunomide in Combination With Vemurafenib in Patients With V600 Mutant Metastatic Melanoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Leflunomide (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Apr 2017 Status changed from suspended to discontinued.
    • 13 Sep 2016 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2017.
    • 13 Sep 2016 Planned End Date changed from 1 Dec 2015 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top